GlassScriptPhysician profile
Jessica J Moon
NPI 1952749681
$1,058.40
in general payments reported to CMS, 2019-2025
12 companies · $325 in 2025
The $325 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $209 · 2021: $12.55 · 2022: $45.47 · 2023: $52.85 · 2024: $255 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $223.77 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $213.65 | 2019-2020 | |
| Glaukos Corporation | $136.97 | 2024 | Istent Trabecular Micro-Bypass System Model Is3, Gts100_glaukos Istent Trabecular Micro-Bypass Stent System |
| Alcon Vision LLC | $129.13 | 2022-2025 | Rocklatan, Tryptyr |
| Abbvie INC. | $99.15 | 2022-2025 | |
| Rxsight INC | $84.14 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Aerie Pharmaceuticals, INC. | $51.45 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $38.56 | 2024 | Envista Mx60 Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.02 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.08 | 2019 | |
| New World Medical,INC. | $15.24 | 2022-2023 | |
| Notal Vision, INC. | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.